Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications

Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications

Abstract Background Approximately 90% of pancreatic ductal adenocarcinoma (PDAC) cases are driven by the untargetable non‐G12C KRAS mutations, and only a small subset of patients are eligible for FDA‐approved precision therapies. The practice of precision therapy in pancreatic cancer was limited by...

Full description

Bibliographic Details
Main Authors: Zhiming Zhao, Xiaomo Li, Fei Wang, Yong Xu, Si Liu, Quanli Han, Zhiying Yang, Weiwei Huang, Zhuzeng Yin, Qu Liu, Haidong Tan, Tonghui Ma, Shuang Si, Jia Huang, Hongling Yuan, Wei Li, Rong Liu
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Cancer Medicine
Subjects:
cancer risk
genetic alterations
next‐generation sequencing
pancreatic cancer
precision therapy
Online Access:https://doi.org/10.1002/cam4.5871

Internet

https://doi.org/10.1002/cam4.5871

Similar Items